SCHEMBL279991

SCHEMBL279991

Cc1ccc(C(=O)NNc2ccccn2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
NPC1 O15118 8/20 0.51
RAB9A P51151 7/20 0.51
KMT2A Q03164 5/20 0.51
MITF O75030 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 4/20 0.47
TP53 P04637 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 4/20 0.45
KDM4E B2RXH2 2/20 0.45
HTT P42858 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
MAPT P10636 1/20 0.45
GFER P55789 1/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162524 0.85 NPC1 (0.69) SMN1; SMN2NPC1RAB9AKMT2AMITF
SCHEMBL280066 0.83 GAA (0.52) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13006697 0.82 GAA (0.49) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL14395985 0.81 GAA (0.50) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL25234792 0.77 GAA (0.56) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL279906 0.77 HPGD (0.55) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL17799224 0.77 L3MBTL1 (0.48) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13060617 0.75 GAA (0.66) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL5523952 0.74 GAA (0.65) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL12195535 0.74 HPGD (0.71) SMN1; SMN2NPC1RAB9AKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20100310536-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2010-12-09 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL GAA 2220/4885SMN1; SMN2 1437/4885NPC1 3107/4885
US-20100310536-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND HCLS1, CD44, NES GAA 624/4885SMN1; SMN2 495/4885NPC1 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.